Anesthesiology and Pain Medicine

Published by: Kowsar

Efficacy of Botulinum Toxin Type A for Treating Chronic Low Back Pain

Seyed M. Jazayeri 1 , Alireza Ashraf 1 , Habib M. Fini 1 , Hajar Karimian 1 , * and Mohamadreza V. Nasab 2
Authors Information
1 Department of Physical Medicine and Rehabilitation, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Physical Medicine and Rehabilitation, Shahid Sadughi University of Medical Sciences, Yazd, Iran
Article information
  • Anesthesiology and Pain Medicine: September 23, 2011, 1 (2); 77-80
  • Published Online: September 26, 2011
  • Article Type: Research Article
  • Received: July 8, 2011
  • Revised: August 25, 2011
  • Accepted: August 30, 2011
  • DOI: 10.5812/kowsar.22287523.1845

To Cite: Jazayeri S M, Ashraf A, Fini H M, Karimian H, Nasab M V. Efficacy of Botulinum Toxin Type A for Treating Chronic Low Back Pain, Anesth Pain Med. 2011 ; 1(2):77-80. doi: 10.5812/kowsar.22287523.1845.

Abstract
Copyright © 2011, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J. 2008; 8(1): 8-20[DOI][PubMed]
  • 2. National Institute of Neurological Disordersand Stroke. Low Back Pain Fact Sheet.;
  • 3. Tamcan O, Mannion AF, Eisenring C, Horisberger B, Elfering A, Muller U. The course of chronic and recurrent low back pain in the general population. Pain. 2010; 150(3): 451-7[DOI][PubMed]
  • 4. Foster NE, Thomas E, Bishop A, Dunn KM, Main CJ. Distinctiveness of psychological obstacles to recovery in low back pain patients in primary care. Pain. 2010; 148(3): 398-406[DOI][PubMed]
  • 5. Mason VL, Skevington SM, Osborn M. Assessing the properties of the WHOQOL-Pain: quality of life of chronic low back pain patients during treatment. Clin J Pain. 2010; 26(7): 583-92[DOI][PubMed]
  • 6. Guzman J, Esmail R, Karjalainen K, Malmivaara A, Irvin E, Bombardier C. Withdrawn: Multidisciplinary bio-psycho-social rehabilitation for chronic low-back pain. Cochrane Database Syst Rev. 2006; 18(2)
  • 7. Brin MF. Basic and clinical aspects of BOTOX. Toxicon. 2009; 54(5): 676-82[DOI][PubMed]
  • 8. Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006; 9(2-3): 145-8[DOI][PubMed]
  • 9. Quagliato EM, Carelli EF, Viana MA. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia. Clin Neuropharmacol. 2010; 33(1): 22-6[PubMed]
  • 10. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001; 56(11): 1523-8[DOI][PubMed]
  • 11. Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev Neurother. 2007; 7(6): 637-47[DOI][PubMed]
  • 12. Molenaers G, Schorkhuber V, Fagard K, Van Campenhout A, De Cat J, Pauwels P, et al. Long-term use of botulinum toxin type A in children with cerebral palsy: treatment consistency. Eur J Paediatr Neurol. 2009; 13(5): 421-9[DOI][PubMed]
  • 13. Ong LC, Wong SW, Hamid HA. Treatment of drooling in children with cerebral palsy using ultrasound guided intraglandular injections of Botulinum Toxin A. J Pediatr Neurol. 2009; 7(2): 141-5
  • 14. Seifart A, Unger M, Burger M. Functional electrical stimulation to lower limb muscles after botox in children with cerebral palsy. Pediatr Phys Ther. 2010; 22(2): 199-206[DOI][PubMed]
  • 15. Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008; 89(5): 799-806[DOI][PubMed]
  • 16. Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm. 2008; 115(4): 617-23[DOI][PubMed]
  • 17. Jost WH. Botulinum toxin in multiple sclerosis. J Neurol. 2006; 253-20[DOI][PubMed]
  • 18. Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol. 2010; 184(3): 1011-6[DOI][PubMed]
  • 19. Schapiro RT. Managing the symptoms of multiple sclerosis. 2007;
  • 20. Bahman J. Botulinum toxin treatment of low back pain and fibromyalgia. Toxicon. 2008; 51: 48[DOI]
  • 21. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001; 56(10): 1290-3[DOI][PubMed]
  • 22. Jabbari B. Treatment of chronic low back pain with botulinum neurotoxins. Curr Pain Headache Rep. 2007; 11(5): 352-8[DOI][PubMed]
  • 23. Nagarajan V, Al-Shubaili A, Ayad YM, Alexander J, Al-Ramezi K. Low back ache treatment with botulinum neurotoxin type A. Local experience in Kuwait. Med Princ Pract. 2007; 16(3): 181-6[DOI][PubMed]
  • 24. Ney JP, Difazio M, Sichani A, Monacci W, Foster L, Jabbari B. Treatment of chronic low back pain with successive injections of botulinum toxin a over 6 months: a prospective trial of 60 patients. Clin J Pain. 2006; 22(4): 363-9[DOI][PubMed]
  • 25. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983; 17(1): 45-56[DOI]
  • 26. Fairbank JC, Couper J, Davies JB, O'Brien JP. The Oswestry low back pain disability questionnaire. Physiotherapy. 1980; 66(8): 271-3[PubMed]
  • 27. Price DD, Bush FM, Long S, Harkins SW. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. Pain. 1994; 56(2): 217-26[DOI]
  • 28. Jabbari B, Ney J, Sichani A, Monacci W, Foster L, Difazio M. Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study. Pain Med. 2006; 7(3): 260-4[DOI][PubMed]
  • 29. Subin B, Saleemi S, Morgan G, Zavisca F, Cork R. Treatment of Chronic Low Back Pain by Local Injection of Botulinum Toxin-A. Internet J Pain, Symptom Control and Palliat Care. 2003; 2(2)
  • 30. Dressler D. Botulinum toxin mechanisms of action. Suppl Clin Neurophysiol. 2004; 57: 159-66[DOI]
  • 31. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008; 64(3): 274-83[DOI][PubMed]
  • 32. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000; 38(2): 245-58[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments